



LEO Pharma

– a pioneer
in medical
dermatology

Thorsten Thormann
President, Research & Early Development

Founded in 1908

More than 100 years of experience in helping patients



We are committed to helping patients longterm



Psoriasis



Thrombosis



Atopic dermatitis

Our ambition is to be a global leader in medical dermatology



EUR 1,359 million
in 2020 revenue



6,000
employees



21% of revenue
reinvested in R&D



960 scientists and
specialists in R&D



Products sold in
130 countries




Founded in
Denmark in 1908

Majority owned by
the LEO Foundation


SALES BY REGION 2020

EUR million



SALES BY THERAPEUTIC AREA 2020

EUR million



*Contract manufacturing organizations

OUR THERAPEUTIC AREAS



Psoriasis



Eczema



Skin infections



Acne



Rosacea




Rare skin diseases



Thrombosis

MULTIPLE DRUG DELIVERY SYSTEMS



Injections



Topicals





Tablets

Advancing science in dermatology


Project*	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration	
PIPELINE Q4-2021								
Delgocitinib LP0133	A topical pan-JAK inhibitor under development for chronic hand eczema.							
Anti IgE⁺B-cell LP0201	A monoclonal antibody under development for atopic dermatitis and allergic asthma.							
Anti IL-22R LP0145	An anti-inflammatory monoclonal antibody under development for atopic dermatitis.							
H4R antagonist LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for atopic dermatitis.							
IL-17A PPI LP0200	An IL-17 small-molecule modulator under development for psoriasis.							

*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.

 Finalized phase  Current phase




Our Global R&D footprint



Collaboration with Academia


Ongoing 40-50 global collaborations accessing talents, patients, science and insights



R&D investments 2017-2021

Significant double-digit R&D ratio over the past years


Costs¹ MEUR



R&D ratio²



Staffing # FTE




1: Excluding depreciations and intangible investments/write-offs
2: Total R&D expenses/Net sales


R&D 2021 split by Portfolio and cost type

Majority of R&D expenses goes to our innovative portfolio – Clinical trials a key cost driver

Portfolio split



Cost type



Clinical cost per phase (external spend)

